ACADIA Pharmaceuticals Inc.
ACAD
$16.62
$0.301.84%
| Weiss Ratings | ACAD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D+ | |||
| Reward Grade | C | |||
| Rating Factors | ACAD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Fair | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ACAD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.46 | |||
| Price History | ACAD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -3.54% | |||
| 30-Day Total Return | -15.51% | |||
| 60-Day Total Return | -9.72% | |||
| 90-Day Total Return | 2.53% | |||
| Year to Date Total Return | -10.93% | |||
| 1-Year Total Return | -8.23% | |||
| 2-Year Total Return | -12.20% | |||
| 3-Year Total Return | -36.61% | |||
| 5-Year Total Return | -60.12% | |||
| 52-Week High % Change | -21.08% | |||
| 52-Week Low % Change | 15.34% | |||
| Price | ACAD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $20.68 | |||
| 52-Week Low Price | $14.15 | |||
| 52-Week Low Price (Date) | Oct 23, 2024 | |||
| 52-Week High Price (Date) | Feb 21, 2025 | |||
| Valuation | ACAD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.72B | |||
| Enterprise Value | 2.02B | |||
| Price/Earnings (TTM) | 12.03 | |||
| Earnings Per Share (TTM) | 1.36 | |||
| Earnings Per Share Growth | -448.69% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.84 | |||
| Price/Book (Q) | 3.71 | |||
| Enterprise Value/Revenue (TTM) | 2.11 | |||
| Price | $16.62 | |||
| Enterprise Value/EBITDA (TTM) | 17.54 | |||
| Enterprise Value/EBIT | 20.35 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | ACAD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 166.70M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ACAD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 558 2871 | |||
| Address | 12830 El Camino Real San Diego, CA 92130 | |||
| Website | www.acadia.com | |||
| Country | United States | |||
| Year Founded | 1993 | |||
| Profitability | ACAD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 10.35% | |||
| Profit Margin | 23.64% | |||
| Management Effectiveness | ACAD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 6.40% | |||
| Return on Equity | 38.89% | |||
| Income Statement | ACAD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 957.80M | |||
| Total Revenue (TTM) | 957.80M | |||
| Revenue Per Share | $5.75 | |||
| Gross Profit (TTM) | 572.71M | |||
| EBITDA (TTM) | 115.06M | |||
| EBIT (TTM) | 99.18M | |||
| Net Income (TTM) | 226.45M | |||
| Net Income Avl. to Common (TTM) | 226.45M | |||
| Total Revenue Growth (Q YOY) | 12.36% | |||
| Earnings Growth (Q YOY) | 213.87% | |||
| EPS Diluted (TTM) | 1.36 | |||
| EPS Diluted Growth (Q YOY) | 213.27% | |||
| Balance Sheet | ACAD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 755.99M | |||
| Cash Per Share (Q) | $4.54 | |||
| Total Current Assets (Q) | 938.32M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 732.79M | |||
| Current Ratio (Q) | 2.376 | |||
| Book Value Per Share (Q) | $4.40 | |||
| Total Assets (Q) | 1.19B | |||
| Total Current Liabilities (Q) | 394.87M | |||
| Total Debt (Q) | 52.00M | |||
| Total Liabilities (Q) | 454.96M | |||
| Total Common Equity (Q) | 732.79M | |||
| Cash Flow | ACAD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -30.54M | |||
| Cash from Financing (TTM) | 6.85M | |||
| Net Change in Cash (TTM) | 133.93M | |||
| Levered Free Cash Flow (TTM) | 279.39M | |||
| Cash from Operations (TTM) | 157.72M | |||
